K Health, an AI-based primary care platform, has secured $50m in funding, with Claure Group leading the investment round.
This financial boost involves contributions from Royalty Pharma founder and CEO Pablo Legorreta and support from existing investors such as Mangrove Capital Partners, Valor Equity Partners, and Atreides Management.
Valued at approximately $900m, according to Bloomberg sources, K Health plans to utilise this investment to enhance its AI capabilities and expand its reach throughout the US.
K Health CEO Allon Bloch stated that the funds will be channelled into refining the company's K Health's AI technology and fostering growth across the US. This includes integration with more health systems, further reported the news agency.
The company’s approach includes the use of peer-reviewed, clinical-grade AI to streamline primary care.
K Health's AI co-pilot system guides patients through a personalised chat, analyses their medical history from Electronic Medical Records (EMRs), and provides healthcare providers with a comprehensive medical chart. This process allows for more accurate diagnoses and individualised treatment plans.
According to the company, this AI-assisted model elevates the quality of care and reduces costs compared to conventional primary care.
The platform's co-pilot feature enables healthcare providers to focus on patient engagement and exercise clinical judgment. It also supports the establishment of thorough follow-up care programmes.
K Health asserts that its model significantly enhances care quality while simultaneously reducing expenses.
K Health is developing a longitudinal care programme in collaboration with leading health systems.
This initiative aims to merge virtual care with physical healthcare facilities, thereby creating scalable access to primary care.
The integrated care delivery model combines the AI co-pilot, EMRs, and the health system's physical infrastructure to guide patients within the system, including arranging diagnostic tests and speciality care.
